VINCOV-19 / Vins Bioproducts - LARVOL DELTA

VINS Bioproducts gets DCGI nod to start clinical trials for VINCOV-19, a therapeutic product against Coronavirus (The Economic Times) - "Hyderabad based VINS Bioproducts Limited on Monday announced that it will start clinical trials for VINCOV-19, a product for coronavirus treatment, in partnership with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad. VINCOV-19 is a new therapeutic product developed from immunisation of horses with spike glycoprotein of the inactivated Covid virus to form antibodies and the resultant antisera — the blood serum containing antibodies. This antisera can be injected into humans infected with Covid-19 to neutralise the virus."

New trial • Infectious Disease • Novel Coronavirus Disease